Benzinga | Nov 17, 2021 06:09AM EST

Merck and Ridgeback To Present Phase 3 Data For Molnupiravir At American Society Of Tropical Medicine And Hygiene (ASTMH) 2021 Annual Meeting

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that new Phase 3 data for molnupiravir, an investigational oral COVID-19 antiviral medicine, will be presented as a late-breaking poster (#LB-5319) at the American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting taking place virtually from Nov. 17-21. Poster data will be available on Wednesday, Nov. 17 at 9 a.m. ET and presented during Poster Session C from 11 a.m.-12:30 p.m. ET on Saturday, Nov. 20.